LKQ Guides FY20 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, automobile parts maker LKQ Corp. (LKQ) initiated earnings and organic revenue growth guidance for the full-year 2020.

For fiscal 2020, the company now projects earnings in a range of $2.20 to $2.32 per share and adjusted earnings in a range of $2.46 to $2.58 per share on organic revenue growth for parts & services of 0.5 to 2.5 percent.

On average, 13 analysts polled by Thomson Reuters expect the company to report earnings of $2.55 per share on revenue growth of 2.2 percent to $12.79 billion for the year. Analysts' estimates typically exclude special items.

"In fiscal 2020, we will continue to focus on our productivity initiatives across each operating segment while managing the ongoing macro headwinds in Europe and the uncertainties relating to other geopolitical events," stated Dominick Zarcone, President and Chief Executive Officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
Follow RTT